Bank Of New York Mellon Corp Trevena Inc Transaction History

Bank Of New York Mellon Corp

  • $528 Trillion
  • Q2 2024

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
SELL
$0.2 - $0.5 $82,789 - $206,973
-413,947 Reduced 83.71%
80,567 $33,000
Q1 2022

May 11, 2022
SELL
$0.41 - $0.63 $3,644 - $5,600
-8,890 Reduced 1.77%
494,514 $272,000
Q4 2021

Feb 11, 2022
BUY
$0.57 - $1.29 $5,135 - $11,621
9,009 Added 1.82%
503,404 $293,000
Q3 2021

Nov 12, 2021
SELL
$1.11 - $1.7 $4,704 - $7,204
-4,238 Reduced 0.85%
494,395 $608,000
Q2 2021

Aug 11, 2021
BUY
$1.46 - $2.25 $541,877 - $835,085
371,149 Added 291.13%
498,633 $842,000
Q1 2021

May 13, 2021
SELL
$1.77 - $2.93 $63,374 - $104,908
-35,805 Reduced 21.93%
127,484 $228,000
Q4 2020

Feb 09, 2021
BUY
$2.13 - $3.26 $245,597 - $375,891
115,304 Added 240.29%
163,289 $349,000
Q3 2020

Nov 12, 2020
SELL
$1.53 - $3.13 $43,320 - $88,622
-28,314 Reduced 37.11%
47,985 $143,000
Q2 2020

Aug 12, 2020
BUY
$0.48 - $1.75 $1,936 - $7,059
4,034 Added 5.58%
76,299 $114,000
Q1 2020

May 06, 2020
SELL
$0.56 - $0.97 $1,056 - $1,830
-1,887 Reduced 2.54%
72,265 $41,000
Q3 2019

Nov 07, 2019
SELL
$0.81 - $1.06 $48,416 - $63,359
-59,773 Reduced 44.63%
74,152 $71,000
Q2 2019

Aug 12, 2019
BUY
$0.94 - $1.6 $56,186 - $95,636
59,773 Added 80.61%
133,925 $138,000
Q1 2019

May 14, 2019
BUY
$0.51 - $1.88 $24,039 - $88,617
47,137 Added 174.48%
74,152 $116,000
Q3 2018

Nov 09, 2018
SELL
$1.39 - $2.25 $1 - $2
-1 Reduced -0.0%
27,015 $0
Q2 2018

Aug 06, 2018
SELL
$1.44 - $2.24 $238,636 - $371,212
-165,720 Reduced 85.98%
27,016 $39,000
Q1 2018

May 15, 2018
BUY
$1.51 - $2.06 $16,631 - $22,688
11,014 Added 6.06%
192,736 $316,000
Q4 2017

Feb 09, 2018
BUY
$1.4 - $2.6 $254,410 - $472,477
181,722
181,722 $291,000

About TREVENA INC

TRVN Quotes by TradingView
  • Ticker TRVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 173,680,992
  • Market Cap $650M
  • Description
  • Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV...
More about TRVN
Track This Portfolio

Track Bank Of New York Mellon Corp Portfolio

Follow Bank Of New York Mellon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email